Mark Stroh
I am an experienced leader in Translational and Quantitative Clinical Pharmacology supporting pre-IND through Phase 3 and post-marketing... | United States
*50 free lookup(s) per month.
No credit card required.
Mark Stroh’s Emails ms****@in****.com
Mark Stroh’s Phone Numbers No phone number available.
Social Media
Mark Stroh’s Location United States
Mark Stroh’s Expertise I am an experienced leader in Translational and Quantitative Clinical Pharmacology supporting pre-IND through Phase 3 and post-marketing development of small molecules, biologics, and novel formats across several disease areas including oncology, neurology, endocrine, cardiovascular, infectious disease, and rare disease. Where I excel: • Building and leading technical teams • Cross functional leadership • Model informed drug development • Driving successful INDs, NDAs, and BLAs Highlights: • Demonstrated record of team building and mentorship, with significant experience building new functions from the ground up • Champion of effective teamwork in developing a wide array of modalities, including small molecule, biologics, and novel format > Small Molecule: Key contributor to FIH-Phase 3, DDI, ADME, biopharmaceutic, and special population study protocols and CSRs. > Biologics: Both functional area lead and cross-functional accountable (Pharmacology Subteam Leader) roles for approval of TECENTRIQ (atezolizumab) valued at 2.68 billion in 2023. > Novel Format: Functional area head for multiple monoclonal, ADC, and TCB prodrug INDs. > Novel format: Functional area head for the first ever systemically administered CRISPR therapies. Specialties: Cross-Disciplinary Leadership; Drug Development & Clinical Trials; Clinical Pharmacology; Translational Sciences; Team Building & Leadership; Model Informed Drug Development; Small Molecule Therapies; ADME; DDI; Special Populations; Biopharmaceutics; Biologics; Immunotherapies; Immunogenicity; Novel Format; Prodrugs; CRISPR; Genome Editing; Regulatory Interactions; IND; NDA/ BLA; Executive Presentations; Project & Vendor Management; Partnerships & Collaboration
Mark Stroh’s Current Industry Metsera
Mark
Stroh’s Prior Industry
Merck
|
Genentech
|
Cytomx Therapeutics
|
Intellia Therapeutics
|
Metsera
Not the Mark Stroh you were looking for?
Find accurate emails & phone numbers for over 700M professionals.
Work Experience
Metsera
Senior Vice President, Pharmacology
Wed May 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) — Present
Intellia Therapeutics
Vice President and Head, Clinical Pharmacology
Thu Apr 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) — Mon Jan 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Cytomx Therapeutics
Vice President and Head, Clinical Pharmacology, QSP, and Pharmacometrics
Tue Nov 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) — Mon Mar 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Genentech
Senior Scientist, Clinical Pharmacology
Mon Oct 01 2012 00:00:00 GMT+0000 (Coordinated Universal Time) — Sat Oct 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Merck
Senior Investigator, Clinical PK/PD
Mon Nov 01 2004 00:00:00 GMT+0000 (Coordinated Universal Time) — Wed Jun 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time)Skills
Languages
Mark Stroh Email Addresses
FAQ About Mark Stroh
-
Mark Stroh is located at
United States -
Mark Stroh is a
I am an experienced leader in Translational and Quantitative Clinical Pharmacology supporting pre-IND through Phase 3 and post-marketing development of small molecules, biologics, and novel formats across several disease areas including oncology, neurology, endocrine, cardiovascular, infectious disease, and rare disease. Where I excel: • Building and leading technical teams • Cross functional leadership • Model informed drug development • Driving successful INDs, NDAs, and BLAs Highlights: • Demonstrated record of team building and mentorship, with significant experience building new functions from the ground up • Champion of effective teamwork in developing a wide array of modalities, including small molecule, biologics, and novel format > Small Molecule: Key contributor to FIH-Phase 3, DDI, ADME, biopharmaceutic, and special population study protocols and CSRs. > Biologics: Both functional area lead and cross-functional accountable (Pharmacology Subteam Leader) roles for approval of TECENTRIQ (atezolizumab) valued at 2.68 billion in 2023. > Novel Format: Functional area head for multiple monoclonal, ADC, and TCB prodrug INDs. > Novel format: Functional area head for the first ever systemically administered CRISPR therapies. Specialties: Cross-Disciplinary Leadership; Drug Development & Clinical Trials; Clinical Pharmacology; Translational Sciences; Team Building & Leadership; Model Informed Drug Development; Small Molecule Therapies; ADME; DDI; Special Populations; Biopharmaceutics; Biologics; Immunotherapies; Immunogenicity; Novel Format; Prodrugs; CRISPR; Genome Editing; Regulatory Interactions; IND; NDA/ BLA; Executive Presentations; Project & Vendor Management; Partnerships & Collaboration Metsera -
Mark Stroh currently works in the
Metsera -
Mark Stroh specializes in
I am an experienced leader in Translational and Quantitative Clinical Pharmacology supporting pre-IND through Phase 3 and post-marketing development of small molecules, biologics, and novel formats across several disease areas including oncology, neurology, endocrine, cardiovascular, infectious disease, and rare disease. Where I excel: • Building and leading technical teams • Cross functional leadership • Model informed drug development • Driving successful INDs, NDAs, and BLAs Highlights: • Demonstrated record of team building and mentorship, with significant experience building new functions from the ground up • Champion of effective teamwork in developing a wide array of modalities, including small molecule, biologics, and novel format > Small Molecule: Key contributor to FIH-Phase 3, DDI, ADME, biopharmaceutic, and special population study protocols and CSRs. > Biologics: Both functional area lead and cross-functional accountable (Pharmacology Subteam Leader) roles for approval of TECENTRIQ (atezolizumab) valued at 2.68 billion in 2023. > Novel Format: Functional area head for multiple monoclonal, ADC, and TCB prodrug INDs. > Novel format: Functional area head for the first ever systemically administered CRISPR therapies. Specialties: Cross-Disciplinary Leadership; Drug Development & Clinical Trials; Clinical Pharmacology; Translational Sciences; Team Building & Leadership; Model Informed Drug Development; Small Molecule Therapies; ADME; DDI; Special Populations; Biopharmaceutics; Biologics; Immunotherapies; Immunogenicity; Novel Format; Prodrugs; CRISPR; Genome Editing; Regulatory Interactions; IND; NDA/ BLA; Executive Presentations; Project & Vendor Management; Partnerships & Collaboration -
Mark Stroh speaks the following languages:
No languages available. -
Mark Stroh has prior experience in the following industries:
Intellia Therapeutics , Cytomx Therapeutics , Genentech , Merck -
Mark Stroh has the following professional experience:
Metsera , Intellia Therapeutics , Cytomx Therapeutics , Genentech , Merck . -
You can view Mark Stroh’s
LinkedIn profile at LinkedIn URL. -
Mark Stroh’s work email addresses are
[email protected] . -
Mark Stroh works at
Metsera
People you may be interested in
- Elissa Wenthe
- Wayne Carlson
- User Info Missing
- Takeshi Hamamoto
- Cb Lim
- Robson Salles
- Melina Montana
- Mary Myatt
Dean School of Arts and Sciences at Upper Iowa University
Vice President Finance
Senior transportation officer
Manager at Rhodia
Chief Client Officer at Marsh
Yr na Google
Corredor de turno en Mostaza y Pan S.A
Founder Myatt & Co, Huh Academy and The Teachers' Collection. Here to share insights on learning, leadership and the curriculum